Breaking News Instant updates and real-time market news.

CEMP

Cempra

$22.59

-0.52 (-2.25%)

16:24
10/04/16
10/04
16:24
10/04/16
16:24

Cempra presents analysis showing rates of failure for existing CABP antibiotics

Cempra announced the presentation of three abstracts based upon analyzing treatment failures with existing antibiotics from more than 400,000 records of patients diagnosed with community-acquired bacterial pneumonia, CABP, in a large U.S. insurance claims database. The data analysis will be presented at the annual Academy of Managed Care Pharmacy Nexus meeting in National Harbor, MD from October 3-6, 2016. These patient records were analyzed to assess rates of failure to the most commonly prescribed antibiotics to treat CABP. Treatment failure was defined as antibiotic prescription refill, new antibiotic claim, emergency room visit, or hospitalization occurring within 30 days of initial therapy. This analysis showed that more than one out of five adult CABP patients failed initial antibiotic monotherapy, with the failure rate exceeding one out of four for an elderly population with certain comorbidities. In a separate analysis of the same database, an association was observed between macrolide-resistant S. pneumoniae, the most common cause of CABP, and macrolide treatment failure by region in the U.S., with the frequency of macrolide-resistant S. pneumoniae as high as 64 percent in the West South Central region of the U.S. Nationwide, the average frequency of macrolide-resistant S. pneumoniae was approximately 49 percent. "These data, showing a high level of macrolide resistance and a high level of treatment failure with the most commonly used antibiotics in CABP, highlight the urgent need for new treatment options for CABP," said Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra.

  • 04

    Nov

  • 27

    Dec

CEMP Cempra
$22.59

-0.52 (-2.25%)

06/24/16
NEED
06/24/16
NO CHANGE
Target $48
NEED
Buy
Needham expects 'moderate success' for Cempra Solithera
After attending the company's investor day, Needham analyst Alan Carr says that he expects Cempra to have moderate success in commercializing its Solithera independently, due to challenges for a biotech company in penetrating urgent and primary care. However, and despite believing that the commercial opportunity is probably larger in hands of Big Pharma, the analyst thinks the company's share price does not reflect what Cempra can accomplish independently. He reiterates a Buy rating and $48 price target on the shares.
06/24/16
06/24/16
NO CHANGE

Needham sees Brexit making EU drug reviews 'less efficient, more expensive'
Needham analyst including Alan Carr, Chad Messer, Danielle Brill and Esther Pang noted that if Article 50 is invoked following the Brexit vote, the European Medicines Agency will need to move out of its current base in London and the U.K. will need to create its own separate regulatory organization for drugs, concluding that Brexit will lead to a "less efficient, more expensive, and potentially lengthier regulatory process" for drug approval in the EU and the U.K. Among the companies that are currently in discussions with the EMA or have drugs under MAA review, Needham lists ACADIA (ACAD) Celator (CPXX), Cempra (CEMP), Gilead (GILD) Intercept (ICPT), Seattle Genetics (SGEN), Valeant (VRX) and Progenics (PGNX).
07/12/16
JPMS
07/12/16
INITIATION
Target $31
JPMS
Overweight
Cempra initiated with an Overweight at JPMorgan
JPMorgan analyst Jessica Fye started Cempra with an Overweight rating and $31 price target. The analyst sees a "high probability of Fast Track US approval" by year-end for Solithera, a new antibiotic for community acquired pneumonia in adults. The analyst believes current share levels offer an attractive entry point.
09/13/16
RAJA
09/13/16
INITIATION
Target $32
RAJA
Outperform
Cempra initiated with an Outperform at Raymond James
Raymond James analyst Christopher Raymond initiated Cempra with an Outperform and a $32 price target. He believes Cempra's lead antibiotic Solithera holds a unique value proposition, the efficacy of a macrolide with improved barrier to resistance and a more favorable safety profile over fluoroquinolones. Raymond's 2025 end-market revenue estimate of $904 million assumes solely CAP usage, leaving other opportunities as call options.

TODAY'S FREE FLY STORIES

NUGT

Direxion Gold Miners Bull

$33.69

-1.66 (-4.70%)

06:40
09/21/17
09/21
06:40
09/21/17
06:40
Technical Analysis
Direxion Gold Miners Bull: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNUG

Direxion Daily Jr Gld Mnrs Bull 3X Shrs

$18.82

-1.03 (-5.19%)

06:39
09/21/17
09/21
06:39
09/21/17
06:39
Technical Analysis
Direxion Daily Jr Gld Mnrs Bull 3X Shrs: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DUST

Direxion Daily Gold Miners Bear 3X ETF

$24.34

1.09 (4.69%)

06:39
09/21/17
09/21
06:39
09/21/17
06:39
Technical Analysis
Direxion Daily Gold Miners Bear 3X ETF: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JDST

Direxion Daily Junior Gold Miners Index Bear 3x Shares

$54.48

2.67 (5.15%)

06:38
09/21/17
09/21
06:38
09/21/17
06:38
Technical Analysis
Direxion Daily Junior Gold Miners Index Bear 3x Shares: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VXX

iPath S&P 500 VIX Short-Term Futures

$40.98

0.07 (0.17%)

06:37
09/21/17
09/21
06:37
09/21/17
06:37
Technical Analysis
iPath S&P 500 VIX Short-Term Futures: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XIV

VelocityShares Daily Inverse VIX Short-Term ETN

$93.36

-0.23 (-0.25%)

06:37
09/21/17
09/21
06:37
09/21/17
06:37
Technical Analysis
VelocityShares Daily Inverse VIX Short-Term ETN: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TVIX

VelocityShares Daily 2x VIX Short-Term ETN

$12.45

0.06 (0.48%)

06:36
09/21/17
09/21
06:36
09/21/17
06:36
Technical Analysis
VelocityShares Daily 2x VIX Short-Term ETN: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SVXY

ProShares Short VIX Short-Term Futures

$89.64

-0.09 (-0.10%)

06:36
09/21/17
09/21
06:36
09/21/17
06:36
Technical Analysis
ProShares Short VIX Short-Term Futures: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALV

Autoliv

$122.59

1.04 (0.86%)

06:36
09/21/17
09/21
06:36
09/21/17
06:36
Recommendations
Autoliv analyst commentary  »

Autoliv price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

USO

United States Oil Fund

$10.24

0.13 (1.29%)

06:35
09/21/17
09/21
06:35
09/21/17
06:35
Technical Analysis
United States Oil Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XOP

SPDR Oil Exploration and Production Fund

$32.86

0.68 (2.11%)

06:35
09/21/17
09/21
06:35
09/21/17
06:35
Technical Analysis
SPDR Oil Exploration and Production Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGAZ

VelocityShares 3x Inv Natural Gas ETN

$21.73

0.61 (2.89%)

06:34
09/21/17
09/21
06:34
09/21/17
06:34
Technical Analysis
VelocityShares 3x Inv Natural Gas ETN: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UGAZ

VelocityShares 3x Long Natural Gas ETN

$13.20

-0.36 (-2.65%)

06:34
09/21/17
09/21
06:34
09/21/17
06:34
Technical Analysis
VelocityShares 3x Long Natural Gas ETN: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMD

AMD

$13.74

0.62 (4.73%)

, NVDA

Nvidia

$185.84

-1.51 (-0.81%)

06:34
09/21/17
09/21
06:34
09/21/17
06:34
Recommendations
AMD, Nvidia, Tesla analyst commentary  »

Tesla partnership would…

AMD

AMD

$13.74

0.62 (4.73%)

NVDA

Nvidia

$185.84

-1.51 (-0.81%)

TSLA

Tesla

$373.91

-1.19 (-0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

EWZ

MSCI Brazil Index

$43.19

0.13 (0.30%)

06:34
09/21/17
09/21
06:34
09/21/17
06:34
Technical Analysis
MSCI Brazil Index: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EFA

iShares MSCI EAFE Index Fund

$68.32

-0.15 (-0.22%)

06:33
09/21/17
09/21
06:33
09/21/17
06:33
Technical Analysis
iShares MSCI EAFE Index Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNK

SPDR Barclays High Yield Bond

$37.21

-0.01 (-0.03%)

06:33
09/21/17
09/21
06:33
09/21/17
06:33
Technical Analysis
SPDR Barclays High Yield Bond: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SJB

ProShares Short High Yield

$23.19

0.0092 (0.04%)

06:32
09/21/17
09/21
06:32
09/21/17
06:32
Technical Analysis
ProShares Short High Yield: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AUO

AU Optronics

$4.19

-0.03 (-0.71%)

06:32
09/21/17
09/21
06:32
09/21/17
06:32
Periodicals
AU Optronics to continue 'smart investment' policy, DigiTimes reports »

AU Optronics Chairman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HYG

iShares iBoxx $ High Yield Corporate Bond

$88.45

-0.01 (-0.01%)

06:32
09/21/17
09/21
06:32
09/21/17
06:32
Technical Analysis
iShares iBoxx $ High Yield Corporate Bond: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$120.82

-0.15 (-0.12%)

06:32
09/21/17
09/21
06:32
09/21/17
06:32
Technical Analysis
iShares iBoxx $ Investment Grade Corporate Bond: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLT

iShares 20+ Year Treasury Bond Fund

$125.91

0.09 (0.07%)

06:31
09/21/17
09/21
06:31
09/21/17
06:31
Technical Analysis
iShares 20+ Year Treasury Bond Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSM

TSMC

$37.82

-0.48 (-1.25%)

, QCOM

Qualcomm

$51.98

-0.32 (-0.61%)

06:31
09/21/17
09/21
06:31
09/21/17
06:31
Periodicals
TSMC seen grabbing up to 80% of ordres for Qualcomm's PWM IC, DigiTimes says »

Taiwan Semi (TSM) is…

TSM

TSMC

$37.82

-0.48 (-1.25%)

QCOM

Qualcomm

$51.98

-0.32 (-0.61%)

SMI

SMIC

$5.65

0.19 (3.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

P

Pandora

$8.23

-0.09 (-1.08%)

, AAPL

Apple

$156.07

-2.66 (-1.68%)

06:31
09/21/17
09/21
06:31
09/21/17
06:31
Periodicals
Music subscriptions accelerate in first half of 2017, WSJ reports »

In the U.S., revenue from…

P

Pandora

$8.23

-0.09 (-1.08%)

AAPL

Apple

$156.07

-2.66 (-1.68%)

GOOG

Alphabet

$931.58

9.77 (1.06%)

GOOGL

Alphabet Class A

$947.54

10.68 (1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 29

    Nov

SLV

iShares Silver Trust

$16.19

-0.17 (-1.04%)

06:29
09/21/17
09/21
06:29
09/21/17
06:29
Technical Analysis
iShares Silver Trust: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.